Insights

Innovative inflammasome Adiso focuses on novel inflammasome inhibitors including ADS032 targeting NLRP1 and NLRP3, presenting a differentiated entry point for inflammatory disease therapy and potential collaborations with larger biopharma seeking dual-pathway inflammation control.

Strategic partnerships Existing collaboration with Hospital Health and funding from Morningside Ventures indicate a readiness to co-develop and co-commercialize, suggesting sales opportunities through alliance models, licensing discussions, or joint development agreements.

Early stage to mid Program portfolio spans discovery to phase 2 (UC, CDI, and UC) with a novel inflammasome program, signaling a need for CRO, clinical ops, and manufacturing partners to scale trials and accelerate timelines for potential out-licensing or acquisition targets.

Live biotherapeutic ADS024 SS-LBP offers a unique modality in inflammatory disease treatment, creating a potential entry point for specialty distributors, contract manufacturers, and regulatory strategy consultants to support development, manufacturing, and commercialization readiness.

Financial runway With a funding level around 60 million and revenue in the low single-digit millions, there is appetite for strategic partnerships, licensing deals, or milestone-driven collaborations to extend runways and de-risk late-stage development.

Similar companies to Adiso Therapeutics

Adiso Therapeutics Tech Stack

Adiso Therapeutics uses 8 technology products and services including iCIMS, WordPress, Shopify, and more. Explore Adiso Therapeutics's tech stack below.

Adiso Therapeutics's Email Address Formats

Adiso Therapeutics uses at least 3 email formats:
Adiso Therapeutics Email FormatsExamplePercentage
FLast@adisotx.comJDoe@adisotx.com
77%
First.Last@adisotx.comJohn.Doe@adisotx.com
16%
Last.First@adisotx.comDoe.John@adisotx.com
7%

Frequently Asked Questions

What is Adiso Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Adiso Therapeutics's official website is adisotx.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Adiso Therapeutics generate?

Minus sign iconPlus sign icon
As of October 2026, Adiso Therapeutics's annual revenue is estimated to be $1M - $10M.

What is Adiso Therapeutics's SIC code and NAICS code?

Minus sign iconPlus sign icon
Adiso Therapeutics's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Adiso Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2026, Adiso Therapeutics has approximately 10 employees across 2 continents, including North America and Europe. Key team members include Owner: A. A. Explore Adiso Therapeutics's employee directory with LeadIQ.

What industry does Adiso Therapeutics belong to?

Minus sign iconPlus sign icon
Adiso Therapeutics operates in the Biotechnology Research industry.

What technology does Adiso Therapeutics use?

Minus sign iconPlus sign icon
Adiso Therapeutics's tech stack includes iCIMS, WordPress, Shopify, Microsoft 365, Really Simple Discovery, Slider Revolution, WP Engine and Piwik PRO Core.

What is Adiso Therapeutics's email format?

Minus sign iconPlus sign icon
Adiso Therapeutics's email format typically follows the pattern of FLast@adisotx.com. Find more Adiso Therapeutics email formats with LeadIQ.

How much funding has Adiso Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2026, Adiso Therapeutics has raised $60M in funding. The last funding round occurred on Mar 10, 2022 for $60M.

When was Adiso Therapeutics founded?

Minus sign iconPlus sign icon
Adiso Therapeutics was founded in 2022.
Adiso Therapeutics logo

Adiso Therapeutics

Biotechnology ResearchMassachusetts, United States2-10 Employees

Adiso Therapeutics is a biotechnology research company based in Concord, Massachusetts, focused on developing medicines for inflammatory diseases. It aims to address limitations of existing therapies, which often fail to halt disease progression or raise safety concerns. The company pursues novel programs, including ADS032, an inhibitor of inflammasomes associated with NLRP1 and NLRP3, and ADS024, a single-strain live biotherapeutic product with a distinctive mechanism. 

Its target market includes patients affected by inflammatory diseases and the clinicians who treat them, seeking therapies with improved efficacy and safety. In October 2023, the company announced the appointment of Robert Lisicki to its board of directors, marking governance expansion.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2022
Employees
2-10

Section iconFunding & Financials

  • $60M

    Adiso Therapeutics has raised a total of $60M of funding over 1 rounds. Their latest funding round was raised on Mar 10, 2022 in the amount of $60M as a Series A.

  • $1M - $10M

    Adiso Therapeutics's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.